AstraZeneca's Voydeya granted EC approval to treat rare blood disease PNH pmlive.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pmlive.com Daily Mail and Mail on Sunday newspapers.
AstraZeneca (AZN) Announces Voydeya Approval in EU as add-on to ravulizumab or eculizumab streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Positive phase 3 trial results showed that danicopan was more effective than placebo when treating extravascular hemolysis in paroxysmal nocturnal hemoglobinuria.
AstraZeneca announces that Voydeya has been approved in the U.S. as an adjunctive therapy to Ultomiris or Soliris in the treatment of extravascular hemolysis in adults with paroxysmal nocturnal.
AstraZeneca's Voydeya (danicopan) has been approved in the US as add-on therapy for PNH patients with EVH. Find out more about this breakthrough treatment.